Q1 Earnings Estimate for Genelux Issued By HC Wainwright

Genelux Co. (NASDAQ:GNLX) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Genelux in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.16) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.22) EPS and FY2029 earnings at $2.58 EPS.

Genelux Stock Performance

Genelux stock opened at $3.40 on Wednesday. The company has a market capitalization of $117.43 million, a price-to-earnings ratio of -3.58 and a beta of -1.41. The company’s 50 day simple moving average is $4.02 and its 200-day simple moving average is $3.09. Genelux has a 1 year low of $1.60 and a 1 year high of $6.50.

Institutional Trading of Genelux

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Genelux in the 4th quarter valued at $25,000. Apollon Wealth Management LLC increased its stake in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after purchasing an additional 2,857 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Genelux during the fourth quarter worth about $41,000. Brown Brothers Harriman & Co. boosted its stake in shares of Genelux by 76.2% in the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after purchasing an additional 9,114 shares during the period. Finally, D.A. Davidson & CO. acquired a new position in shares of Genelux in the fourth quarter valued at approximately $51,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.